Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Airbender : Is this a good entry point you think?
Jaguar8 OP Airbender : I don’t give that advice. Likely this will get attention Monday